Company Filing History:
10 out of 10 
1 out of 3,539 
Years Active: 2018-2025
Title: Fahar Merchant: Innovator in Oncolytic Virus Research
Introduction
Fahar Merchant is a prominent inventor based in Vancouver, Canada, known for his significant contributions to the field of cancer research. With a total of 10 patents to his name, he has made remarkable strides in developing innovative therapies aimed at treating cancer through advanced methodologies.
Latest Patents
Among his latest patents is a groundbreaking invention titled "Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof." This invention provides an oncolytic virus vector that contains a sequence encoding IL-4 receptor targeted cargo protein, including IL-4 muteins and/or IL-13 muteins. The oncolytic virus encoded from this invention is utilized for treating cancer, showcasing its potential in therapeutic applications. Another notable patent is "IL-2 superagonists in combination with anti-PD-1 antibodies." This patent presents human interleukin-2 (IL-2) muteins or variants that exhibit an increased binding capacity for the IL-2Rβ receptor compared to wild-type IL-2. These muteins are designed for use in combination therapies with anti-PD-1 antibodies, further enhancing cancer treatment options.
Career Highlights
Fahar Merchant has worked with esteemed organizations such as Medicenna Therapeutics, Inc. and the National Institutes of Health, a component of the US Department of Health & Human Services. His work in these institutions has allowed him to contribute significantly to the advancement of cancer therapies and research.
Collaborations
Throughout his career, Fahar has collaborated with notable colleagues, including Raj K Puri and Bharatkumar H Joshi. These collaborations have fostered a productive environment for innovation and research in the field of oncology.
Conclusion
Fahar Merchant's innovative work in oncolytic virus research and cancer treatment exemplifies his dedication to advancing medical science. His patents and collaborations highlight his significant impact on the field, making him a key figure in the ongoing fight against cancer.